Literature DB >> 10086327

Lowering of trichosanthin immunogenicity by site-specific coupling to dextran.

W L Chan1, P C Shaw, X B Li, Q F Xu, X H He, S C Tam.   

Abstract

Trichosanthin is a type I ribosome-inactivating protein possessing a broad spectrum of biological and pharmacological activities. Therapeutic use of this compound is hampered by its immunogenicity. It was shown earlier that coupling of dextran to trichosanthin can increase plasma half-life and reduce antigenicity. However, the site where dextran attaches to trichosanthin cannot be controlled; ideally, it should be at or near the antigenic determinant. The present study attempted to couple dextran to trichosanthin at a potential antigenic site. By site-directed mutagenesis, two sites, R29 and K173, were replaced by cysteine, and dextran was coupled to the newly created cysteine residues. The dextran-trichosanthin complex retained 50% of abortifacient activity and had a mean residence time in rats 27-fold longer than natural trichosanthin. Acute hypersensitivity reaction in guinea pigs was reduced greatly after coupling of K173C (a trichosanthin mutant with lysine-173 replaced by cysteine) to dextran. Compared with natural trichosanthin, dextran-K173C had a decrease in IgG and IgE response, whereas the coupling of R29C (a trichosanthin mutant with arginine-29 replaced by cysteine) to dextran did not show significant reduction of immunogenicity. This suggests that K173 but not R29 is located at or near an antigenic determinant. This study has demonstrated an alternative approach for mapping of antigenic determinants. The information obtained is also useful in producing an improved trichosanthin derivative for therapeutic use.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10086327     DOI: 10.1016/s0006-2952(98)00364-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  3 in total

1.  Novel purification method and antibiotic activity of recombinant Momordica charantia MAP30.

Authors:  Ching-Dong Chang; Ping-Yuan Lin; Yo-Chia Chen; Han-Hsiang Huang; Wen-Ling Shih
Journal:  3 Biotech       Date:  2017-04-07       Impact factor: 2.406

Review 2.  Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins.

Authors:  Francesco Giansanti; David J Flavell; Francesco Angelucci; Maria Serena Fabbrini; Rodolfo Ippoliti
Journal:  Toxins (Basel)       Date:  2018-02-13       Impact factor: 4.546

Review 3.  Engineering of Ribosome-inactivating Proteins for Improving Pharmacological Properties.

Authors:  Jia-Qi Lu; Zhen-Ning Zhu; Yong-Tang Zheng; Pang-Chui Shaw
Journal:  Toxins (Basel)       Date:  2020-03-09       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.